C-arm computed tomography compared with positron emission tomography/computed tomography for treatment planning before radioembolization.
The purpose of this study was to determine whether rotational C-arm computed tomography (CT) allows visualization of liver metastases and adds relevant information for radioembolization (RE) treatment planning. Technetium angiography, together with C-arm CT, was performed in 47 patients to determine the feasibility for RE. C-arm CT images were compared with positron emission tomography (PET)/CT images for the detection of liver tumors. The images were also rated according one of the following three categories: (1) images that provide no additional information compared with DSA alone; (2) images that do provide additional information compared with DSA; and (2) images that had an impact on eligibility determination for and planning of the RE procedure. In all patients, 283 FDG-positive liver lesions were detected by PET. In venous contrast-phase CT, 221 (78.1%) and 15 (5.3%) of these lesions were either hypodense or hyperdense, respectively. In C-arm CT, 103 (36.4%) liver lesions were not detectable because they were outside of either the field of view or the contrast-enhanced liver segment. Another 25 (8.8%) and 98 (34.6%) of the liver lesions were either hyperdense or presented primarily as hypodense lesions with a rim enhancement, respectively. With PET/CT as the standard of reference, venous CT and C-arm CT failed to detect 47 (16.6%) and 57 (20.1%) of all liver lesions, respectively. For RE planning, C-arm CT provided no further information, provide some additional information, or had an impact on the procedure in 20 (42.5%), 15 (31.9%) and 12 (25.6%) of patients, respectively. We conclude that C-arm CT may add decisive information in patients scheduled for RE.
Department of Clinical Radiology, Ludwig-Maximilians-University Hospital, 81377, Munich, Germany. christoph.becker@med.uni-muenchen.de
Christoph
C
Becker
Tobias
T
Waggershauser
Reinhold
R
Tiling
Sabine
S
Weckbach
Thorsten
T
Johnson
Oliver
O
Meissner
Klaus
K
Klingenbeck-Regn
Maximilian
M
Reiser
Ralf Thorsten
RT
Hoffmann
D015901:Angiography, Digital Subtraction; D003287:Contrast Media; D004621:Embolization, Therapeutic; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007472:Iohexol / Q000031:analogs & derivatives; D007479:Iopamidol / Q000031:analogs & derivatives; D008113:Liver Neoplasms / Q000000981:diagnostic imaging* / Q000556:secondary; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D009366:Neoplasm Seeding; D049268:Positron-Emission Tomography / Q000379:methods*; D015641:Radiography, Interventional; D019275:Radiopharmaceuticals; D013668:Technetium Tc 99m Aggregated Albumin; D014057:Tomography, X-Ray Computed / Q000379:methods*; D015021:Yttrium Radioisotopes
D003287:Contrast Media; D019275:Radiopharmaceuticals; D013668:Technetium Tc 99m Aggregated Albumin; D015021:Yttrium Radioisotopes; C057937:iomeprol; D007472:Iohexol; C038192:iopromide; D007479:Iopamidol